Lv4
548 积分 2023-09-15 加入
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies
2天前
已完结
Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation
1个月前
已完结
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
1个月前
已完结
Abstract 6711: Combinations of belantamab mafodotin with lenalidomide, pomalidomide, bortezomib and/or dexamethasone synergize in vitro and potentiate in vivo anti-tumor activity in multiple myeloma
1个月前
已关闭
Abstract 6711: Combinations of belantamab mafodotin with lenalidomide, pomalidomide, bortezomib and/or dexamethasone synergize in vitro and potentiate in vivo anti-tumor activity in multiple myeloma
1个月前
已关闭
Long‐term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO)
3个月前
已完结
The real-world efficacy and safety of frontline therapy of obinutuzumab plus bendamustine for untreated high-tumor-burden follicular lymphoma
3个月前
已关闭
Zanubrutinib for the treatment of Bing–Neel syndrome
3个月前
已完结
Clinical significance of MYD88 non‐L265P mutations in diffuse large B‐cell lymphoma
3个月前
已完结
Multiple myeloma
4个月前
已完结
皖公网安备34019202002308
